Genocea Biosciences Inc Precio/Ventas
¿Qué es el Precio/Ventas de Genocea Biosciences Inc?
El Precio/Ventas de Genocea Biosciences Inc es 0.07
¿Cuál es la definición de Precio/Ventas?
El ratio precio / ventas es el precio de las acciones de una empresa en comparación con sus ingresos.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Precio/Ventas de compañías en Sector Health Care en NASDAQ en comparadas con Genocea Biosciences Inc
¿Qué hace Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Empresas con precio/ventas similar a Genocea Biosciences Inc
- CESC tiene Precio/Ventas de 0.07
- Pivot Technology Solutions tiene Precio/Ventas de 0.07
- Flexituff Ventures International tiene Precio/Ventas de 0.07
- Dorel Industries tiene Precio/Ventas de 0.07
- Conduity Capital Plc tiene Precio/Ventas de 0.07
- UniVision Engineering tiene Precio/Ventas de 0.07
- Genocea Biosciences Inc tiene Precio/Ventas de 0.07
- North Asia Strategic tiene Precio/Ventas de 0.07
- Redsun Properties tiene Precio/Ventas de 0.07
- United Natural Foods tiene Precio/Ventas de 0.07
- Vintana Plc tiene Precio/Ventas de 0.07
- Wai Chun Bio-Technology tiene Precio/Ventas de 0.07
- Farm Pride Foods tiene Precio/Ventas de 0.07